Navigation Links
Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products

SCHAUMBURG, Ill. and MORRISTOWN, N.J., May 4 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, and Actavis Inc., a leading global generic pharmaceutical manufacturer, have launched an exclusive collaboration to develop and market a select group of specialty injectable medications for the United States.

Under the agreement, Actavis will develop, obtain U.S. Food and Drug Administration approval, and supply the products, which Sagent will market in the United States. Financial terms of the agreement have not been disclosed.

"Actavis' impressive injectable pipeline, substantial development and supply capabilities and excellent record of execution make Actavis an outstanding partner for Sagent," said Jeffrey M. Yordon, Sagent's chief executive officer, founder and chairman of the board. "This collaboration complements Sagent's strategy by quickly adding products to our marketed portfolio and we look forward to working with Actavis to expand our collective portfolio."

Doug Boothe, chief executive officer of Actavis Inc., said the strategic collaboration with Sagent will enable consumers in the United States to benefit from the company's global expertise in developing and manufacturing specialty injectable products.

"By combining our injectable pipeline with Sagent's and partnering with their sales and marketing team, we have increased our potential to serve the U.S. market for these valuable products beyond what either of our companies could have achieved independently," Boothe said. Headquartered in Morristown, N.J., Actavis Inc. is the U.S. subsidiary of Iceland-based Actavis Group.  

About Sagent Pharmaceuticals

Sagent Pharmaceuticals is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.

To Discover Injectables Excellence™ and learn more about Sagent, please visit

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one quarter of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ; Little Falls, NJ; Totowa, NJ; and Lincolnton, NC. Actavis also has research and development facilities in Owings Mills, MD and Sunrise, FL; and a packaging facility in Totowa, NJ. Please visit for more information.

SOURCE Sagent Pharmaceuticals, Inc.; Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
2. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
3. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
4. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
5. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
6. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
7. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
8. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
9. Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
10. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
11. ISTA Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference
Post Your Comments:
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... at the recent 2015 American Dental Association meeting in Washington D.C. revolved around the ... protect a patient’s overall health. The talk stressed the link between periodontal disease (more ...
(Date:11/27/2015)... ... 2015 , ... A team of Swiss doctors has released a report on ... just posted the findings on the website. Click here to read the details ... mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the 106 ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... 2015 , ... Intellitec Solutions announced today that they have ... as Microsoft’s official group for end users of Dynamics SL ERP software, the ... experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
Breaking Medicine News(10 mins):